JP2023528826A5 - - Google Patents

Info

Publication number
JP2023528826A5
JP2023528826A5 JP2022573673A JP2022573673A JP2023528826A5 JP 2023528826 A5 JP2023528826 A5 JP 2023528826A5 JP 2022573673 A JP2022573673 A JP 2022573673A JP 2022573673 A JP2022573673 A JP 2022573673A JP 2023528826 A5 JP2023528826 A5 JP 2023528826A5
Authority
JP
Japan
Prior art keywords
seq
variable region
amino acid
acid sequence
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573673A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528826A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/064326 external-priority patent/WO2021239935A1/en
Publication of JP2023528826A publication Critical patent/JP2023528826A/ja
Publication of JP2023528826A5 publication Critical patent/JP2023528826A5/ja
Pending legal-status Critical Current

Links

JP2022573673A 2020-05-29 2021-05-28 Sars関連コロナウイルスに対する中和抗体 Pending JP2023528826A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20177354.6 2020-05-29
EP20177354 2020-05-29
EP20182325.9 2020-06-25
EP20182325 2020-06-25
EP20213562.0 2020-12-11
EP20213562 2020-12-11
PCT/EP2021/064326 WO2021239935A1 (en) 2020-05-29 2021-05-28 Neutralizing antibodies against sars-related coronavirus

Publications (2)

Publication Number Publication Date
JP2023528826A JP2023528826A (ja) 2023-07-06
JP2023528826A5 true JP2023528826A5 (cg-RX-API-DMAC7.html) 2024-06-05

Family

ID=76250344

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573673A Pending JP2023528826A (ja) 2020-05-29 2021-05-28 Sars関連コロナウイルスに対する中和抗体

Country Status (6)

Country Link
US (1) US20210371503A1 (cg-RX-API-DMAC7.html)
EP (1) EP4157455A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023528826A (cg-RX-API-DMAC7.html)
CA (1) CA3180556A1 (cg-RX-API-DMAC7.html)
TW (1) TW202210504A (cg-RX-API-DMAC7.html)
WO (1) WO2021239935A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
MX2022014598A (es) 2020-05-26 2023-03-31 Regeneron Pharma Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno.
CR20220660A (es) 2020-06-03 2023-02-17 Regeneron Pharma Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2
EP4259200A1 (en) * 2020-12-11 2023-10-18 Boehringer Ingelheim International GmbH Formulation for multi-purpose application
AU2022221297A1 (en) * 2021-02-09 2023-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies targeting the spike protein of coronaviruses
WO2022263638A1 (en) * 2021-06-17 2022-12-22 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
EP4370210A1 (en) 2021-07-14 2024-05-22 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2023150307A2 (en) * 2022-02-03 2023-08-10 Abpro Corporation Compositions and methods against a virus
CN118388640A (zh) * 2022-09-30 2024-07-26 郴州市第一人民医院 一种全人源抗新型冠状病毒SARS-CoV-2的广谱抗体及其应用
WO2025194069A1 (en) * 2024-03-15 2025-09-18 Atreca, Inc. Anti-csp antibody variants

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 感染性の呼吸性疾患の治療方法
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5985320A (en) 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US6323322B1 (en) 1997-04-30 2001-11-27 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
ES2198922T3 (es) 1998-06-24 2004-02-01 Advanced Inhalation Research, Inc. Particulas porosas grandes emitadas por un inhalador.
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2005040219A1 (en) 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
MX2018006072A (es) 2015-11-19 2018-08-01 Squibb Bristol Myers Co Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.

Similar Documents

Publication Publication Date Title
Weltzin et al. Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice
US7504107B2 (en) Methods of priming the immunogenic activity of vaccines useful for eliciting a protective immune response
JP2023517236A5 (cg-RX-API-DMAC7.html)
JP2020523004A5 (cg-RX-API-DMAC7.html)
JP2016512554A5 (cg-RX-API-DMAC7.html)
CN1132516A (zh) 抗呼吸道合胞体病毒的单克隆IgA抗体
JPH06501928A (ja) ウイルス性呼吸器系疾患の予防または治療のためのエーロゾル
JPWO2019044926A1 (ja) 抗HSV gBモノクローナル抗体又はその抗原結合断片
Pan et al. Development of horse neutralizing immunoglobulin and immunoglobulin fragments against Junín virus
JP2021511043A5 (cg-RX-API-DMAC7.html)
Lamarre et al. Protection from lethal coronavirus infection by immunoglobulin fragments.
CN1437482A (zh) 用于治疗变态反应的重组的或纯化的多克隆抗体
JP2022531205A5 (cg-RX-API-DMAC7.html)
JP2010504759A (ja) ライノウイルスの新規中和性免疫原(nimiv)およびワクチン応用のためのその利用
CN113329767A (zh) 肠道病毒对vero细胞的适应及其疫苗制剂
Bahadir et al. Monoclonal antibodies for pediatric viral disease prevention and treatment
US9872895B2 (en) TLR5 ligands, therapeutic methods, and compositions related thereto
KR20210084535A (ko) 개변 CMV gB 단백질 및 이것을 포함하는 CMV 백신
CN111840532A (zh) 预防病毒性传染病的活疫苗
JP2022513438A5 (cg-RX-API-DMAC7.html)
CN108430502A (zh) 诺瓦克病毒疫苗
US20230081039A1 (en) Pharmaceutical composition comprising polynucleotides and use thereof for prevention or treatment of covid-19
JP2022553703A5 (cg-RX-API-DMAC7.html)
AU2013322559B2 (en) Passive immunisation against influenza, in particular H5N1
JP2022544613A5 (cg-RX-API-DMAC7.html)